Standards of Medical Care in Diabetes-2018, Diabetes Care, 41, 2018. https://diabetesed.net/wp-content/uploads/2017/12/2018-ADA-Standards-of-Care.pdf, 2020年6月1日参照
VR Aroda, J Rosenstock, Y Terauchi, Y Altuntas, NM Lalic, ECM Villegas, OK Jeppesen, E Christiansen, CL Hertz, M Haluzik ; PIONEER 1 Investigators : The PIONEER 1 : Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes, Diabetes Care, 42, 1724-1732 (2019).
HW Rodbard, J Rosenstock, LH Canani, C Deerochanawong, J Gumprecht, SO Lindberg, I Lingvay, AL Sondergaard, MB Treppendahl, E Montanya ; PIONEER 2 Investigators : The PIONEER 2 Trial. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin Diabetes Care, 42, 2272-2281 (2019).
J Rosenstock, D Allison, AL Birkenfeld, TM Blicher, S Deenadayalan, JB Jacobsen, P Serusclat, R Violante, H Watada, M Davies ; PIONEER 3 Investigators : The PIONEER 3 Randomized Clinical Trial. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea, JAMA, 321, 1466-1480 (2019).
R Pratley, A Amod, ST Hoff, T Kadowaki, I Lingvay, M Nauck, KB Pedersen, T Saugstrup, JJ Meier ; for the PIONEER 4 investigators : The PIONEER 4 Trial. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes : a randomised, double-blind, phase 3a trial, Lancet, 394, 39-50 (2019).